B Waeber1, G Leonetti, R Kolloch, G T McInnes. 1. Division of Clinical Physiopathology and Medical Teaching, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Abstract
OBJECTIVE: The Hypertension Optimal Treatment (HOT) study is a large, prospective trial aimed at defining the level of diastolic blood pressure required during anti-hypertensive therapy in order to achieve maximal protection against cardiovascular complications. A further aim is to assess the effects on morbidity and mortality of a 75 mg daily dose of aspirin compared with placebo. SUBJECTS AND METHODS: Compliance with double-blind administration of aspirin or placebo added to anti-hypertensive treatment was evaluated for 1 year in a subset (n = 530) of the study population (n = 18 790) by placing the medication in a container closed with an electronic cap that records precisely the time of each opening. RESULTS: The 1-year compliance rate (percentage of days with one opening per day) could be assessed in 501 patients. It averaged 78.3 +/- 25% in aspirin-treated patients (n = 236, mean +/- SD), compared with 78.5 +/- 25% in patients having received placebo (n = 265), and was not influenced by age, sex or country (Germany, Italy, Switzerland, UK). The compliance rate was also similar irrespective of whether the patients had reached their target blood pressure, but was significantly better during the first than the second 6-month monitoring period (84.1 +/- 22% versus 72.3 +/- 32%, n = 501). CONCLUSIONS: The high rate of compliance with aspirin or placebo observed in the HOT study suggests that the patients were highly motivated and may account for the unusually good blood pressure control achieved in this trial during long-term anti-hypertensive treatment.
RCT Entities:
OBJECTIVE: The Hypertension Optimal Treatment (HOT) study is a large, prospective trial aimed at defining the level of diastolic blood pressure required during anti-hypertensive therapy in order to achieve maximal protection against cardiovascular complications. A further aim is to assess the effects on morbidity and mortality of a 75 mg daily dose of aspirin compared with placebo. SUBJECTS AND METHODS: Compliance with double-blind administration of aspirin or placebo added to anti-hypertensive treatment was evaluated for 1 year in a subset (n = 530) of the study population (n = 18 790) by placing the medication in a container closed with an electronic cap that records precisely the time of each opening. RESULTS: The 1-year compliance rate (percentage of days with one opening per day) could be assessed in 501 patients. It averaged 78.3 +/- 25% in aspirin-treated patients (n = 236, mean +/- SD), compared with 78.5 +/- 25% in patients having received placebo (n = 265), and was not influenced by age, sex or country (Germany, Italy, Switzerland, UK). The compliance rate was also similar irrespective of whether the patients had reached their target blood pressure, but was significantly better during the first than the second 6-month monitoring period (84.1 +/- 22% versus 72.3 +/- 32%, n = 501). CONCLUSIONS: The high rate of compliance with aspirin or placebo observed in the HOT study suggests that the patients were highly motivated and may account for the unusually good blood pressure control achieved in this trial during long-term anti-hypertensive treatment.
Authors: V-M S Ramanujam; Fatima Nayeem; Karl E Anderson; Yong-Fang Kuo; Nai-Wei Chen; Hyunsu Ju; Lee-Jane W Lu Journal: Biomarkers Date: 2016-12-23 Impact factor: 2.658
Authors: Antoinette Schoenthaler; Franzenith de la Calle; Maria Pitaro; Audrey Lum; William Chaplin; Jazmin Mogavero; Milagros C Rosal Journal: J Gen Intern Med Date: 2019-10-17 Impact factor: 5.128
Authors: Marco Valgimigli; Hector M Garcia-Garcia; Bernard Vrijens; Pascal Vranckx; Eugène P McFadden; Francesco Costa; Karen Pieper; David M Vock; Min Zhang; Gerrit-Anne Van Es; Pierluigi Tricoci; Usman Baber; Gabriel Steg; Gilles Montalescot; Dominick J Angiolillo; Patrick W Serruys; Andrew Farb; Stephan Windecker; Adnan Kastrati; Antonio Colombo; Fausto Feres; Peter Jüni; Gregg W Stone; Deepak L Bhatt; Roxana Mehran; Jan G P Tijssen Journal: Eur Heart J Date: 2019-07-01 Impact factor: 29.983